pharma industry

Trump's efforts to lower drug prices have prompted European countries to prepare defensive measures. The UK has capitulated to pharmaceutical industry lobbying, while some EU member states have pledged to resist such pressures.

David Meek acquired Bluebird Bio (now rebranded as Genetix) when it was near bankruptcy and claims to have transformed it in a year. He predicts the company will treat 1,000 patients annually for sickle cell disease gene therapies by 2030.